Travere officer sells shares, receives stock awards

Travere Therapeutics Chief Research Officer William E. Rote reported routine equity compensation and a planned share sale.

Rhea-AI Filing Summary

Travere Therapeutics Chief Research Officer William E. Rote reported routine equity compensation and a planned share sale. On 01/31/2026 he acquired 20,090 shares of common stock for $0 through restricted stock units and received an employee stock option for 53,570 shares at an exercise price of $33.095 per share.

These options vest over time, with one-fourth vesting on the first anniversary of grant and the remainder in 36 monthly installments. On 02/03/2026 he sold 12,446 shares of common stock at $32.87 per share under a Rule 10b5-1 trading plan, and held 109,087 common shares and 53,570 options directly afterward.

Insider Trade Summary

Net Seller: 12,446 shares

Net Sell 3 txns

Insider ROTE WILLIAM E.

Role Chief Research Officer

Sold 12,446 shs ($409K)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,446	$32.87	$409K
Grant/Award	Employee stock option (right to buy)	53,570	$0.00	$0.00
Grant/Award	Common Stock	20,090	$0.00	$0.00

Holdings After Transaction: Employee stock option (right to buy) — 53,570 contracts (Direct); Common Stock — 109,087 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.
2. F2. This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.
3. F3. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Travere Therapeutics (TVTX) report for William E. Rote?

Travere Therapeutics reported that Chief Research Officer William E. Rote received new stock awards and sold shares. He acquired 20,090 common shares via restricted stock units, received 53,570 stock options, and sold 12,446 shares at $32.87 per share in early 2026.

How many Travere Therapeutics (TVTX) shares did William E. Rote sell and at what price?

William E. Rote sold 12,446 shares of Travere Therapeutics common stock at $32.87 per share on February 3, 2026. This transaction was reported as a sale code "S" and occurred under a pre-arranged Rule 10b5-1 trading plan adopted in May 2025.

What new equity awards did William E. Rote receive from Travere Therapeutics (TVTX)?

William E. Rote received 20,090 shares of Travere Therapeutics common stock through restricted stock units and an employee stock option for 53,570 shares at a $33.095 exercise price. Both awards were granted on January 31, 2026 as part of his compensation.

What is the vesting schedule for William E. Rote’s Travere Therapeutics (TVTX) stock options?

Rote’s employee stock option vests over time. One-fourth of the 53,570 option shares vest and become exercisable on the first anniversary of the grant date, and the remaining shares vest in 36 equal monthly installments until fully vested by the 2036 expiration.

How many Travere Therapeutics (TVTX) shares does William E. Rote own after these transactions?

After the reported transactions, William E. Rote beneficially owned 109,087 shares of Travere Therapeutics common stock directly. He also held 53,570 employee stock options, giving him rights to purchase additional shares if he exercises those options in the future.

Was William E. Rote’s Travere Therapeutics (TVTX) share sale part of a Rule 10b5-1 plan?

Yes. The 12,446-share sale on February 3, 2026 was executed under a written trading plan adopted May 29, 2025 that meets Rule 10b5-1(c) requirements. The sale included shares sold to cover tax obligations from restricted stock unit vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/03/2026 - 09:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ROTE WILLIAM E.

(Last) (First) (Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DRIVE, STE 300

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Research Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/31/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/31/2026		A(1)		20,090	A	$0	121,533	D
Common Stock	02/03/2026		S(2)		12,446	D	$32.87	109,087	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$33.095	01/31/2026		A		53,570		(3)	01/31/2036	Common Stock	53,570	$0	53,570	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer.

2. This sale was made pursuant to a written plan adopted on May 29, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of restricted stock units.

3. One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.